(Total Views: 555)
Posted On: 11/09/2021 8:16:47 PM
Post# of 148908
But wait, there's more!
RANTES
"It looks like the effort to squash CYTODYN goes all the way to the top of NSF. The complaint was amended as follows:
46. In June of 2021, Dr. Christopher Recknor, the Chief Operating Officer of CytoDyn, contacted Tom Chestnut, the Chief Operating Officer of NSF International, in an attempt to resolve Amarex’s significant failures as CytoDyn’s CRO. During that discussion, Chestnut directed Dr. Recknor to contact Lush. 47. On June 8, 2021, Lush emailed Dr. Recknor and introduced himself as the “Global VP of NSF Health Sciences which includes Amarex.” Lush stated that he had engaged in “detailed discussions” with both Kevan Lawlor—NSF International’s CEO—and Chestnut about CytoDyn’s issues with Amarex, and Lush asked Dr. Recknor not to disclose their discussion to Amarex. 48. Despite Lush’s promise to resolve the problems between Amarex and CytoDyn, Amarex’s performance under the contract did not improve. 3249. Finally, CytoDyn was left with no choice and on August 2, 2021, CytoDyn demanded that Amarex make its facilities available (for a virtual or in person) audit under the MSA. CytoDyn believed this audit was necessary to determine what else Amarex was failing to do and to protect the integrity of its clinical trial programs. 3350. OnAlthough CytoDyn directed its request to exercise its right to an audit to Amarex personnel, on August 9, 2021, Lush responded on behalf of Amarex, indicating that Amarex refused to consent to the audit."
RANTES
"It looks like the effort to squash CYTODYN goes all the way to the top of NSF. The complaint was amended as follows:
46. In June of 2021, Dr. Christopher Recknor, the Chief Operating Officer of CytoDyn, contacted Tom Chestnut, the Chief Operating Officer of NSF International, in an attempt to resolve Amarex’s significant failures as CytoDyn’s CRO. During that discussion, Chestnut directed Dr. Recknor to contact Lush. 47. On June 8, 2021, Lush emailed Dr. Recknor and introduced himself as the “Global VP of NSF Health Sciences which includes Amarex.” Lush stated that he had engaged in “detailed discussions” with both Kevan Lawlor—NSF International’s CEO—and Chestnut about CytoDyn’s issues with Amarex, and Lush asked Dr. Recknor not to disclose their discussion to Amarex. 48. Despite Lush’s promise to resolve the problems between Amarex and CytoDyn, Amarex’s performance under the contract did not improve. 3249. Finally, CytoDyn was left with no choice and on August 2, 2021, CytoDyn demanded that Amarex make its facilities available (for a virtual or in person) audit under the MSA. CytoDyn believed this audit was necessary to determine what else Amarex was failing to do and to protect the integrity of its clinical trial programs. 3350. OnAlthough CytoDyn directed its request to exercise its right to an audit to Amarex personnel, on August 9, 2021, Lush responded on behalf of Amarex, indicating that Amarex refused to consent to the audit."
(8)
(0)Scroll down for more posts ▼
